Immediate Impact
62 standout
Citing Papers
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Standout
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Works of Qifeng Ding being referenced
Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Qifeng Ding | 141 | 164 | 124 | 21 | 364 | |
| M.E. Gleave | 180 | 136 | 169 | 22 | 406 | |
| Yugang Wang | 138 | 152 | 129 | 18 | 373 | |
| Mi Yang | 124 | 130 | 140 | 29 | 361 | |
| Wentao Tian | 85 | 197 | 128 | 15 | 368 | |
| Yumeng Wang | 80 | 153 | 103 | 32 | 388 | |
| Louqian Zhang | 128 | 142 | 134 | 22 | 365 | |
| Hui Guan | 91 | 170 | 104 | 26 | 395 | |
| Xinjian Huang | 64 | 162 | 177 | 25 | 356 | |
| Adrien Costantini | 141 | 271 | 118 | 24 | 391 | |
| Jindong Sheng | 101 | 79 | 146 | 17 | 381 |
All Works
Login with ORCID to disown or claim papers
Loading papers...